AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 116.7% in January

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 127,400 shares, a growth of 116.7% from the December 31st total of 58,800 shares. Based on an average trading volume of 8,500 shares, the short-interest ratio is currently 15.0 days.

AstraZeneca Price Performance

Shares of AZNCF opened at $137.21 on Wednesday. AstraZeneca has a 52-week low of $118.16 and a 52-week high of $175.00. The stock’s 50-day simple moving average is $132.73 and its 200 day simple moving average is $147.29.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.